XTLB Projected Dividend Yield
ADR (Sponsored) (New) 2017/XTL Biopharmaceuticals Ltd ( NASDAQ : XTLB )XTL Biopharmaceuticals is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Co.'s existing drug, hCDR1, is a treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. hCDR1 is also Phase II-ready for the treatment of SS. SS is a chronic autoimmune disorder affecting lacrimal and salivary gland function (glandular) but may also affect other organs and systems (extraglandular) such as the kidneys, and gastrointestinal system, among others. 20 YEAR PERFORMANCE RESULTS |
XTLB Dividend History Detail XTLB Dividend News XTLB Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |